Fate Therapeutics Q2 2025 cash $248.9M; 12% workforce cut; FT819 lupus response durable

FATE THERAPEUTICS INC

2025-Q2 EPS reported -$0.61 vs consensus -$0.35 ▼ miss (-74.6%)

Q2 2025 cash, cash equivalents & investments $248.9M; total revenue $1.9M from Ono collaboration; operating expenses $38.9M.
Board approved 12% workforce reduction; expects severance charges of $0.9M–$1.2M in Q3 2025; cash runway extended through YE 2027.
FT819 SLE/LN: First patient on fludarabine-free conditioning achieved DORIS at 12-month follow-up; first extrarenal SLE patient without conditioning achieved LLDAS at 3 & 6 months.
FDA allowed IND for FT836 MICA/B-targeted CAR T-cell program; Phase 1 to test without conditioning chemotherapy in solid tumors.
Ono collaboration extended for second solid tumor CAR T candidate through at least June 2026.

item 2.02item 2.05item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.